311 results on '"Blom, Kim"'
Search Results
2. High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022
3. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
4. Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study
5. Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022
6. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
7. Divergent clonal differentiation trajectories establish CD8+ memory T cell heterogeneity during acute viral infections in humans
8. Logistics for Rapid Isolation of Viruses From Humans.
9. Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum
10. Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023
11. Humoral immune responses to the monovalent xbb.1.5-adapted bnt162b2 mrna booster in sweden
12. Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum
13. Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023
14. Subjective cognitive decline, brain imaging biomarkers, and cognitive functioning in patients with a history of vascular disease: the SMART-Medea study
15. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
16. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster
17. Hippocampal sulcal cavities: prevalence, risk factors and association with cognitive performance. The SMART-Medea study and PREDICT-MR study
18. Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden
19. SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
20. Mucosal IgA protects against BQ.1 and BQ.1.1 infection
21. SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
22. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose
23. Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden
24. Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection
25. Rapid emergence of omicron sublineages expressing spike protein R346T
26. Mucosal IgA protects against BQ.1 and BQ.1.1 infection
27. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection
28. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose
29. Vaccine-induced correlate of protection against fatal COVID-19 in the old and frail during waves of neutralization resistant variants of concern
30. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial
31. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection
32. Rapid emergence of omicron sublineages expressing spike protein R346T
33. Psychosocial risk factors on hippocampal subfield volumes: the Medea‐7T study
34. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
35. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
36. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial
37. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
38. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
39. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
40. Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers
41. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
42. Clonally heritable gene expression imparts a layer of diversity within cell types
43. sj-pdf-1-jcb-10.1177_0271678X211025447 - Supplemental material for Cortical cerebral microinfarcts on 7T MRI: Risk factors, neuroimaging correlates and cognitive functioning – The Medea-7T study
44. Vascular risk factors, brain changes and cognitive functioning in mid and late life
45. Psychosocial factors and hippocampal subfields: The Medea‐7T study.
46. Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
47. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
48. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination
49. Neutralization of VOCs including Delta one year post COVID-19 or vaccine
50. A hippocampal insulin‐growth factor 2 pathway regulates the extinction of fear memories
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.